Table 1.
Participant characteristics
| EDRN | PCPT* | |||
|---|---|---|---|---|
| No. pts | 645 | 5,519 | ||
| No. pt age (%): | ||||
| 60 or Younger | 301 | (46.7) | 38 | (0.7) |
| 60–64 | 110 | (17.1) | 1,143 | (20.7) |
| 65–69 | 118 | (18.3) | 1,741 | (31.5) |
| 70 or Older | 116 | (18.0) | 2,597 | (47.1) |
| No. race (%): | ||||
| White | 559 | (86.7) | 5,276 | (95.6) |
| African-American | 47 | (7.3) | 175 | (3.2) |
| Other | 39 | (6.0) | 68 | (1.2) |
| No. family history (%):† | ||||
| No | 483 | (74.9) | 4,599 | (83.3) |
| Yes | 162 | (25.1) | 920 | (16.7) |
| No. ng/ml PSA (%): | ||||
| 2 or Less | 66 | (10.2) | 3,603 | (65.3) |
| 2–4 | 159 | (24.7) | 1,285 | (23.3) |
| Greater than 4 | 420 | (65.1) | 631 | (11.4) |
| No. DRE (%): | ||||
| Normal | 510 | (79.1) | 4,968 | (89.9) |
| Abnormal/suspicious | 135 | (20.9) | 551 | (10.1) |
| Median biopsy cores (% with indicated No. cores) | 12 | (81.1) | 6 | (84.5) |
| No. Ca (%) | 280 | (43.4) | 1,211 | (21.9) |
| No. Gleason 7–10 Ca (%) | 168 (26.0 overall, 60.0 Ca) | 257 (4.7 overall, 21.2 Ca) | ||
Differences between cohorts significant for each listed variable, p <0.0001 for each.
*
Number of biopsy cores in PCPT was proscribed by trial protocol.6
†
Whether a father, brother or son had prostate cancer.